Alyeska Investment Group L.P. lifted its stake in shares of Dermira Inc (NASDAQ:DERM) by 1.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 351,059 shares of the biopharmaceutical company’s stock after acquiring an additional 6,270 shares during the quarter. Alyeska Investment Group L.P. owned about 0.84% of Dermira worth $9,479,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Platinum Investment Management Ltd. boosted its stake in Dermira by 28.8% during the 2nd quarter. Platinum Investment Management Ltd. now owns 57,700 shares of the biopharmaceutical company’s stock valued at $1,681,000 after purchasing an additional 12,900 shares during the period. Jennison Associates LLC boosted its stake in Dermira by 0.3% during the 3rd quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock valued at $71,300,000 after purchasing an additional 7,746 shares during the period. Renaissance Technologies LLC bought a new stake in Dermira during the 1st quarter valued at approximately $1,023,000. Schwab Charles Investment Management Inc. boosted its stake in Dermira by 24.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 140,495 shares of the biopharmaceutical company’s stock valued at $4,095,000 after purchasing an additional 27,259 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Dermira by 9.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after purchasing an additional 125,157 shares during the period. Institutional investors own 99.54% of the company’s stock.
Dermira Inc (NASDAQ:DERM) opened at $26.53 on Tuesday. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68. Dermira Inc has a twelve month low of $21.35 and a twelve month high of $38.75.
In other Dermira news, insider Eugene A. Bauer sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total value of $225,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas G. Wiggans sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $27.52, for a total value of $137,600.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,800 shares of company stock valued at $809,425. Insiders own 13.30% of the company’s stock.
WARNING: “Dermira Inc (DERM) Stake Increased by Alyeska Investment Group L.P.” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://sportsperspectives.com/2017/12/12/dermira-inc-derm-stake-increased-by-alyeska-investment-group-l-p.html.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira Inc (NASDAQ:DERM).
Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.